Q4 2023 Medistim ASA Earnings Call Transcript
Good morning, everyone, and welcome to Medistim's fourth quarter and preliminary full year results for 2023 presentation. My name is Kari Eian Krogstad and together with CFO, Thomas Jakobsen will take you through the results. And as always, we will go straight into the highlights for the fourth quarter. So in this quarter, in Norwegian currency, we see a decent quarter for sales.
Absolutely not great, but decent because we're comparing to the strongest quarter we have ever delivered. So a revenue of NOK135.6 million means a decrease in Norwegian currency of 4.4%.
In this picture, we see that our own products are decreasing by 5.8%, while the third-party products is growing by 4.3%. And then we are segmenting our business into imaging products and flow products, also vascular business segment versus the cardiac business segment.
And we see for this quarter that all are down with exceptional vascular sales. And it's good to see that that is still growing at 21.2% this quarter. We also see that currency continued to play an effect
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |